 |
|
A NEW SULFONAMIDE (GANTRISIN®)Studies on Solubility, Absorption and Excretion
FLOYD A. SVEC, M.D.;
PAUL S. RHOADS, M.D.;
JOSEPH H. ROHR, M.D.
Arch Intern Med. 1950;85(1):83-90.
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings. |
|
|
|
A NEW compound, 3,4-dimethyl-5-sulfanilamido-isoxazole (gantrisin®), appears to show considerable promise as an effective sulfonamide; so far in our hands it has produced no renal complications. The antibacterial and clinical effectiveness of this compound has been reported on by Schnitzer and others,1 Sarnoff and others,2 Lazarus,3 Rhoads and others,4 Haines and Miceli,5 Narins6 and Rodgers and Colby.7 It was found by these workers to compare favorably with other commonly used sulfonamides. Their results indicated that it is effective in the treatment of infections of the urinary tract, especially those caused by Escherichia coli. It has also been found to be moderately effective against Proteus. It has been used as the sole bacteriostatic agent in 10 cases of meningococcic meningitis4 with complete recovery.
The toxic manifestations encountered have been similar in nature to those produced with other sulfonamides with the exception of the absence of renal complications.
. . . [Full Text PDF of this Article]
Author Affiliations
With the Assistance of Ida Kraus, Ph.D. CHICAGO
From the Departments of Medicine, Northwestern University Medical School and Wesley Memorial Hospital.
Footnotes
This compound, prepared and supplied by Hoffman-LaRoche, Inc., Nutley, N. J., was formerly known as NU 445.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
|
